# Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Source: https://onco.cc/trials/nct07431281/  
OnCo record `nct07431281` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, Oxaliplatin and Zolbetuximab in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by AstraZeneca, now recruiting.

## Summary

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 is a phase 3 interventional study registered as NCT07431281 by AstraZeneca, with 2130 participants planned, started 2026-02-03 and due to reach its primary completion in 2029-08-16. Interventions recorded: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil and Oxaliplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07431281
- Phase: 3
- Setting: A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
- Sponsor: AstraZeneca
- Enrolled: 2130

## Sources

- ClinicalTrials.gov NCT07431281: https://clinicaltrials.gov/study/NCT07431281

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/), [Zolbetuximab](https://onco.cc/drugs/zolbetuximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07431281.json